Study: NCT05541861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b4 5 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b4 10 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b4 15 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b4 15 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b4 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b4 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b4 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg
Description: Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.